After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. The stock was recently discussed on Yahoo Finance as it revealed that Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Sage Therapeutics Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $26.40 and fluctuated between $26.51 as its day high and $25.54 as its day low. The current market capitalization of Sage Therapeutics Inc is $1.58B. A total of 0.73 million shares were traded on the day, compared to an average of 896.29K shares.
Insider Activity
Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, SAGE has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 11 BUYs and 7 SELLs from insiders. Insiders purchased 39,568 shares during that period but sold 18,210.
In the most recent transaction, Barrett Elizabeth bought 2,000 shares of SAGE for 18.64 per share on Aug 09. After the transaction, the Director now owns 3,000 company shares. In a previous transaction on May 09, Barrett Elizabeth bought 1,000 shares at 50.50 per share. SAGE shares that Director owns now total 1,000.
Among the insiders who sold shares, JONAS JEFFREY M disposed of 11,643 shares on Feb 10 at a per-share price of $44.61. This resulted in the Director holding 121,981 shares of SAGE after the transaction.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for SAGE in the last 3 months, the mean price target is $25.88 with high estimates of $79.00 and low estimates of $18.00. In terms of 52-week highs and lows, SAGE has a high of $59.99 and a low of $16.51.
As of this writing, SAGE has an earnings estimate of $Sage Therapeutics, Inc. per share for the current quarter. EPS was calculated based on a consensus of Spirit Airlines, Inc. estimates, with a high estimate of $SAGE GROUP PLC ORD 1 4/77P per share and a lower estimate of $Safehold Inc. New.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. SAGE’s latest balance sheet shows that the firm has $1.74B in Cash & Short Term Investments as of fiscal 2021. There were $18.43M in debt and $85.19M in liabilities at the time. Its Book Value Per Share was $13.62, while its Total Shareholder’s Equity was $1.73B.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for SAGE is Buy with a score of 3.36.
